TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2019 | AUGMENT study: Post-hoc analysis in MZL

Featured:

Catherine ThieblemontCatherine Thieblemont

Jun 19, 2019


At the 24th Congress of the European Hematology Association (EHA), Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, shares a post-hoc analysis from the AUGMENT study in marginal zone lymphoma (MZL).

The AUGMENT study was a randomized study in patients with relapsed/refractory follicular lymphoma (FL) or MZL (20% of patients, n = 63). Patients were randomized to either R2 (rituximab and lenalidomide) or rituximab and placebo. The primary endpoint was progression-free survival (PFS).
 
At baseline, patients in the R2 arm had bulkier disease and there were significant differences in these baseline characteristics between the two arms. However, in the R2 arm, there was a higher overall response rate (65%) compared to rituximab and placebo (43%). This did not translate to differences in PFS.

AUGMENT study: Post-hoc analysis in MZL